From Data to Practice: Integrating Key Phase III Results into Ovarian Cancer Management-Recording

Video Transcription

Video Summary

This IGCS educational session, led by Dr. Wendell Naumann, Dr. Floor Backus, and Dr. Kathleen Moore, focuses on recent advances in treating platinum-resistant ovarian cancer. Dr. Moore details new phase III clinical trials—Keynote B96, Rosella, and Mirosol—highlighting their positive impacts on patient management. A case study illustrates challenges: a 75-year-old patient with platinum-resistant disease after prior chemotherapy, bevacizumab, and PARP inhibitor treatment.<br /><br />The discussion emphasizes the shift from rigid platinum-resistance definitions toward a broader “platinum-eligible or ineligible” concept, given the decline in response rates and survival with successive therapies. Weekly paclitaxel remains a superior chemotherapy backbone, but newer strategies aim to improve outcomes by prolonging clinical benefit rather than drastically increasing response rates.<br /><br />Key advances include:<br /><br />1. Rosella trial: Combining nab-paclitaxel with the glucocorticoid receptor antagonist relacorrelant improved progression-free survival modestly, with pending overall survival data.<br /><br />2. Keynote B96: Adding pembrolizumab to weekly paclitaxel ± bevacizumab showed statistically significant improvements in progression-free and overall survival in biomarker-selected patients.<br /><br />3. Mirosol trial: The antibody-drug conjugate mirvetuximab targeting folate receptor alpha-high tumors significantly improved both progression-free and overall survival, marking the first novel therapy with an OS benefit in this setting.<br /><br />Therapy sequencing remains unclear, with individual patient biomarkers such as folate receptor alpha levels and additional molecular testing guiding treatment selection. The session underscores the necessity of multimodal approaches involving chemotherapy, targeted agents, immunotherapy, and antibody-drug conjugates. Ongoing research and approvals will continue to refine management, with optimism for improved survival and quality of life among patients with platinum-resistant ovarian cancer.

Keywords

platinum-resistant ovarian cancer

phase III clinical trials

Rosella trial

Keynote B96

Mirosol trial

weekly paclitaxel

immunotherapy

antibody-drug conjugates